Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review - Takeaways - MDSpire

Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review

  • By

  • Vanessa Piechotta

  • Sibylle C. Mellinghoff

  • Caroline Hirsch

  • Alice Brinkmann

  • Claire Iannizzi

  • Nina Kreuzberger

  • Anne Adams

  • Ina Monsef

  • Jannik Stemler

  • Oliver A. Cornely

  • Paul J. Bröckelmann

  • Nicole Skoetz

  • May 31, 2022

  • 0 min

Share

  • 1

    Patients with hematological malignancies are at increased risk for severe COVID-19 outcomes due to immune dysfunction.

  • 2

    COVID-19 vaccines show impaired immune responses in individuals with hematological malignancies compared to the general population.

  • 3

    Research indicates reduced vaccine effectiveness against SARS-CoV-2 variants of concern in immunocompromised patients.

  • 4

    A systematic review aims to evaluate the effectiveness, immunogenicity, and safety of COVID-19 vaccines in patients with hematological malignancies.

  • 5

    Data on vaccine-induced immune responses in hematological malignancy patients is limited, necessitating further investigation.

Original Source(s)

Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review

  • by Vanessa Piechotta, Sibylle C. Mellinghoff, Caroline Hirsch, Alice Brinkmann, Claire Iannizzi, Nina Kreuzberger, Anne Adams, Ina Monsef, Jannik Stemler, Oliver A. Cornely, Paul J. Bröckelmann, Nicole Skoetz

  • May 31, 2022

Related Content